A Phase I, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects.
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2014
Price : $35 *
At a glance
- Drugs P 7435 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Piramal Enterprises
- 31 Aug 2018 Biomarkers information updated
- 25 Nov 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 21 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.